Table 4 Paired sample analyses between baseline and 2-month follow-up on total scores.

From: Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

Measure

Sample size

Baseline

2-month

Pearson R Correlation

significance

T-teststatistic

significance

Mean (SD)

Mean (SD)

n

p

t

p

PSYCHS

151

20.25 (8.65)

16.00 (9.74)

0.69

<0.0001

7.13

<0.0001

BPRS

160

41.27 (9.85)

38.71 (10.14)

0.68

<0.0001

3.84

<0.0001

CDSS

160

5.88 (4.78)

4.98 (4.80)

0.60

<0.0001

2.64

<0.009

NSI

156

18.36 (9.49)

17.92 (10.02)

0.69

<0.0001

0.71

0.478

OASIS

159

8.47 (4.33)

7.45 (4.56)

0.57

<0.0001

3.12

0.002

PGI-S

160

2.48 (0.89)

2.39 (0.84)

0.46

<0.0001

1.23

0.221

GFS

156

6.85 (1.46)

6.91 (1.37)

0.63

<0.0001

−0.66

0.511

GFR

156

6.86 (2.21)

7.01 (2.28)

0.79

<0.0001

−1.27

0.204

SOFAS

151

65.30 (14.05)

66.38 (14.97)

0.82

<0.0001

−1.31

0.195

  1. PSYCHS Positive Symptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS, BPRS Brief Psychiatric Rating Scale, CDSS Calgary Depression Scale for Schizophrenia, NSI Negative Symptom Inventory, OASIS Overall Anxiety Severity and Impairment Scale, PGI-S Patient Global Impression of Severity, GFS Global Functioning: Social Scale, GFR Global Functioning: Role Scale, SOFAS Social Occupational Functioning Scale.
Back to article page